Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Status of the research project: The main complications of arrhythmogenic cardiomyopathies (AC) are sudden death, more rarely heart failure. Recently, data are emerging in favor of an associated role of myocardial inflammation and myocarditis in this pathology, but the impact of inflammation on the presentation and prognosis of the cardiomyopathy, as well as its mechanisms, are not clearly elucidated. To date, endomyocardial biopsy is the gold standard for documenting myocardial inflammation. Aim of the research: To evaluate the interest of a new hybrid PET-MR imaging tool for tissue and metabolic characterization of AC associating MRI and 18F-FDG PET, already used in inflammatory pathologies (cardiac sarcoidosis). Project description: Multicentric observational study of 80 patients with genetic AC undergoing PET-MR. Description of the observed profiles and their impact on the phenotype of the cardiomyopathy and its evolution, study of associated immunological mechanisms, correlation with available anatomopathological data. Expected results and perspectives: first non-invasive description of tissue and metabolic phenotype of AC by PET-MR imaging and its prognostic role, basis for pathophysiological and therapeutic research in case of confirmation of the performances of this imaging for the detection of myocardial inflammation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Maximum Age: 99
Healthy Volunteers: f
View:

• Male and female over 16 years old

Locations
Other Locations
France
CHU Angers
RECRUITING
Angers
CHU Brest
RECRUITING
Brest
CHU de Nantes
RECRUITING
Nantes
AP-HP La Salpêtrière
RECRUITING
Paris
CHU de Rennes
RECRUITING
Rennes
Contact Information
Primary
Nicolas Piriou, PH
nicolas.piriou@chu-nantes.fr
0253482781
Backup
Aurélie Thollet
aurelie.thollet@chu-nantes.fr
0240165279
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 80
Treatments
Patients group
Patients and their relatives affected with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20
Sponsors
Leads: Nantes University Hospital
Collaborators: University Hospital, Paris, University Hospital, Angers, University Hospital, Brest

This content was sourced from clinicaltrials.gov